This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims: Please **amend** the claims as follows:

We claim:

Claim 1. (Currently Amended) A pharmaceutical composition comprising at least one agent as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems[[,]] and further comprising at least one agent as compound II which modulates the biological function of one or several of the Angiopoietin/Tie receptor systems, wherein said compound I and said compound II are not identical to one another.

Claim 2. (Currently Amended) A pharmaceutical composition comprising at least one agent as compound I which is targeted to the endothelium via of one or several of the VEGF/VEGF receptor systems[[,]] and further comprising at least one agent as compound II which modulates the biological function of one or several of the Angiopoietin/Tie receptor systems, wherein said compound I and said compound II are not identical to one another.

Claim 3. (Cancelled)

Claim 4. (Currently Amended) A pharmaceutical composition comprising at least one agent as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems[[,]] and further comprising at least one agent as compound II which is targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems, wherein said compound I and said compound II are not identical to one another.

Claim 5. (Currently Amended) A pharmaceutical composition comprising at least one agent as compound I which is targeted to the endothelium via one or several of the VEGF/VEGF receptor systems[[,]] and further comprising at least one agent as compound II which is targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems, wherein said compound I and said compound II are not identical to one another.

Claim 6. (Currently Amended) A pharmaceutical composition comprising at least one agent as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems[[,]] and further comprising at least one agent as compound II which

is targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, wherein said compound I and said compound II are not identical to one another.

Claim 7. (Currently Amended) A pharmaceutical composition comprising at least one agent as compound I which modulates the biological function of one or several of the Angiopoietin/Tie receptor systems[[,]] and further comprising at least one agent as compound II which is targeted to the endothelium via one or several of the Angiopoetin/Tie receptor systems, wherein said compound I and said compound II are not identical to one another.

Claim 8. (Withdrawn) Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

Claim 9. (Previously Presented) A pharmaceutical composition according to claim 1 which is adopted for simultaneous or separate sequential therapeutic application.

Claim 10. (Previously Presented) A pharmaceutical composition according to claim 1 which comprises as compound I at least one of

a) a compound which inhibits receptor tyrosine kinase activity,

b) a compound which inhibits ligand binding to receptors,

c) a compound which inhibits activation of intracellular signal pathways of the receptors,

d) a compound which inhibits or activates expression of a ligand or of a receptor of the VEGF or Tie receptor system,

e) a delivery system comprising an antibody, a ligand, a high-affinity binding oligonucleotide or oligopeptide, or a liposome, which targets cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,

f) a delivery system comprising an antibody, a ligand, a high-affinity binding oligonucleotide or oligopeptide, or a liposome, which is targeted to the endothelium and induce necrosis or apoptosis,

wherein said compound I and said compound II are not identical to one another.

Claim 11. (Previously Presented) A pharmaceutical composition according to claim 1

which comprises as compound II at least one of

g) a compound which inhibits receptor tyrosine kinase activity,

h) a compound which inhibits ligand binding to receptors,

i) a compound which inhibits activation of intracellular signal pathways of the receptors,

j) a compound which inhibits or activates expression of a ligand or of a receptor of the VEGF or Tie receptor system,

k) a delivery system comprising an antibody, a ligand, a high-affinity binding oligonucleotide or oligopeptide, or a liposome, which targets cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,

l) a delivery system comprising an antibody, a ligand, a high-affinity binding oligonucleotide or oligopeptide, or a liposome, which is targeted to the endothelium and induce necrosis or apoptosis,

wherein said compound I and said compound II are not identical to one another.

Claim 12. (Withdrawn) Pharmaceutical compositions according to claim 1 which comprise as compound I and/or II at least one of Seq. ID Nos. 1-59.

Claim 13. (Withdrawn) Pharmaceutical compositions according to claim 1 which comprise as compound I and/or II SEQ ID NO:60.

Claim 14. (Withdrawn) A pharmaceutical composition according to claim 1 which comprise as compound I and/or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

Claim 15. (Withdrawn) A pharmaceutical composition according to claim 1 which comprise as compound I and/ or II at least one small molecule of general formula I



I,

in which

r has the meaning of 0 to 2,

n has the meaning of 0 to 2;

R_3 und R_4 a) each independently from each other have the meaning of lower alkyl,

b) together form a bridge of general partial formula II,



II,

wherein the binding is via the two terminal C- atoms,

and

m has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

III,

wherein one or two of the ring members T_1,T_2,T_3 ,T_4 has the meaning of nitrogen, and each others have the meaning of CH, and the binding is via the atoms T_1 and T_4;

G has the meaning of C_1 -C_6 - alkyl, C_2 - C_6 – alkylene or C_2 - C_6 – alkenylene; or C_2 - C_6 - alkylene or C_3 -C_6-alkenylene, which are substituted with acyloxy or hydroxy; -CH_2-O-, -CH_2 -S-, -CH_2-NH-, -CH_2-O-CH_2-, -CH_2 -S-CH_2-, -CH_2-NH-CH_2, oxa (-O-), thia (-S-) or imino (-NH-),

A, B, D, E and T independently from each other have the meaning of N or CH , with the provisio that not more than three of these Substituents have the meaning of N,

Q has the meaning of lower alkyl, lower alkyloxy or halogene,

R_1 and R_2 independently from each other have the meaning of H or lower alkyl,

X has the meaning of imino, oxa or thia;

Y has the meaning of hydrogene, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl,

whereas, if more than one rest Z is present (m>2), the substituents Z are equal or different from each other,

and

wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one ore more N-atoms carry an oxygene atom, or a salt thereof,

and/or a compound of general formula IV



IV

in which

A has the meaning of group $=NR^2$,

W has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=NR^8$,

Z has the meaning of the group $=NR^{10}$ or =N-, $-N(R^{10})-(CH_2)_q-$, branched or unbranched C_{1-6}-Alkyl or is the group



or A, Z and R^1 together form the group



m, n and o has the meaning of 0 – 3,

q has the meaning of 1 – 6,

R_a, R_b, R_c, R_d, R_e, R_f independently from each other have the meaning of hydrogen, C_{1-4} alkyl or the group $=NR^{10}$, and/ or R_a and/ or R_b together with R_c and or R_d or R_e together with R_e and/ or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R^1 or R^2,

X has the meaning of group $=NR^9$ or =N-,

Y has the meaning of group $-(CH_2)_p$,

p has the meaning of integer 1-4,

R^1 has the meaning of unsubstituted or optionally substituted with one or more of halogene, C_{1-6}-alkyl, or C_{1-6}-alkyl or C_{1-6}-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

R^2 has the meaning of hydrogen or C_{1-6}-alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R_1,

R^3 has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C_{1-6}-alkyl, C_{1-6}-alkoxy or hydroxy,

R^4 ,R^5, R^6 and R^7 independently from each other have the meaning of hydrogen, halogene or C_{1-6}-alkoxy, C_{1-6}-alkyl or C_{1-6}-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R^5 and R^6 together form the group



,

R^8, R^9 and R^{10} independently from each other have the meaning of hydrogen or C_{1-6}-alkyl,

as well as their isomers and salts,

and/ or a compound of general formula V



V,

in which

R^1 has the meaning of group



in which R^5 is chloro, bromo or the group $-OCH_3$,



in which R^7 is $-CH_3$ or chloro,



in which R^8 is $-CH_3$, fluoro, chloro, or $-CF_3$,

in which R^4 is fluoro, chloro, bromo, $-CF_3$, $-N{=}C$, $-CH_3$,$-OCF_3$ or $-CH_2OH$

in which R^6 is $-CH_3$ or chloro

R^2 has the meaning of pyridyl or the group



and

R^3 has the meaning of hydrogen or fluoro,

as well as their isomers and salts.

Claim 16. (Withdrawn, Currently Amended) A pharmaceutical composition according to claim 15 which ~~comprise~~ comprises as compound I and/or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Claim 17. (Withdrawn, Currently Amended) A pharmaceutical composition according to claim 1 which ~~comprise~~ comprises as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the ~~provision~~ proviso that compound I is not ~~identically~~ identical to compound II.

Claim 18. (Withdrawn, Currently Amended) A pharmaceutical composition according to claim 1 which ~~comprise~~ comprises as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Claim 19. (Withdrawn, Currently Amended) A pharmaceutical composition according to claim 1 which ~~comprise~~ comprises as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.

Claim 20. (Withdrawn, Currently Amended) A pharmaceutical composition according to claim 1 which ~~comprise~~ comprises as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.

Claim 21. (Withdrawn, Currently Amended) A pharmaceutical composition according to claim 1 which ~~comprise~~ comprises as compound I L19 scFv-tTF conjugate and as compound II sTie2.

Claim 22. (Withdrawn) A method of treating tumors, cancers, psoriasis, arthritis, rheumatoide arthritis, hemangioma, angiofribroma, eye diseases, diabetic retinopathy, neovascular glaukoma, kidney diseases, glomerulonephritis, diabetic nephropathie, maligneous nephrosclerosis, thrombic microangiopatic syndrome, transplantation rejections, ~~and~~ glomerulopathy, fibrotic diseases, cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, or for the suppression of the ascites formation or for the suppression of VEGF oedemas in a subject, comprising administering into said subject an effective amount of the pharmaceutical composition of claim 1.

Claim 23. (Withdrawn) A method of treating a tumor or tumor metastasis in a subject, comprising administering into said subject an effective amount of the pharmaceutical composition of claim 1.

Claim 24. (Withdrawn) The pharmaceutical composition of claim 1 wherein compound I is 4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and compound II is sTie2.